Pain Management

Navigating Cannabis use requires more than just an understanding of the endocannabinoid system.

Madison Irwin, PharmD, BCPS, discusses her career pharmacy and how she thinks high rates of chronic pain will impact the field in the coming years.

The calcitonin gene-related peptide monoclonal antibody significantly reduced the number of monthly migraine days.

No medications were associated with improved quality of life or reduced headache duration.

Pain, fatigue, and sleep disturbances are common symptoms with rheumatic diseases.

AMA released its 2024 Overdose Epidemic Report and presented key findings from the past year.

PROMIS scores demonstrated the disparities between reported pain and mental health outcomes.

The FDA has mandated that companies participating in the Opioid Analgesic Risk Evaluation and Mitigation Strategy program provide pre-paid mail-back envelopes for unused or expired opioid medications.

The addition of a 10 mg oxycodone hydrochloride tablet improves dosing flexibility and precision.

Opioid use disorder risk was higher in a cohort of patients with chronic pain without disability.

The 70-plus-page lawsuit is directed at Express Scripts for its dealings with drug manufacturers in fueling the US opioid crisis.

Whether patients present with complaints of an aching muscle from a workout or a sudden twinge in the back, consider recommending these topical analgesics.

Although there has recently been an effort to improve pediatric pain treatment, it is still often underestimated and not adequately managed.

Researchers aimed to determine whether or not opioids were appropriate for treating adolescents experiencing chronic pain.

Catch up on important pain management news from the month of September 2024.

Study findings raise concern about increased pain and disability, poorer pain self-management, and impaired quality of life during adolescence that can continue into young adulthood.

Researchers conducted a meta-analysis and systematic review to determine the efficacy of using antidepressants to treat older adults for knee osteoarthritis pain.

Albert Dahan, MD, PhD, discusses how cebranopadol could fit into the broader landscape of pain management therapies.

“By encouraging active self-management using health coaching principles, the WalkBack intervention might be able to reduce the prevalence of recurrent low back pain and associated burden on health care systems,” wrote investigators.

Mark Garofoli combined personal anecdotes with professional expertise to deliver a compelling presentation on kidney stone pain at this year’s PAINWeek National Conference.

Albert Dahan, MD, PhD, discusses recent data on Tris Pharma’s first-in-class dual-NMR agonist and how it will fit into the broader landscape of pain management therapies.

The “cuddle hormone” plays a powerful role in human behavior and may be an additional option to treat pain and manage opioid addiction.

“Reducing abdominal adiposity may be considered a target for chronic pain management, particularly in those with pain in multiple sites and widespread pain,” wrote investigators.

Whereby gastroparesis can hinder the absorption of oral medications in the stomach, Tonix Pharmaceuticals is promoting alternative migraine treatments that bypass the digestive system.

Tris Pharma will examine the efficacy and safety of cebranopadol in the ALLEVIATE-1 and ALLEVIATE-2 studies.

Focus group participants were receptive to using eHealth tools, but noted several barriers such as cost and availability.

Researchers conducted a systematic review of literature exploring the misuse of opioid prescriptions for patients with chronic non-cancer pain.

Mark Garofoli delves deeper into the challenges men face when it comes to acknowledging pain, underscoring the critical need to dismantle the surrounding stigma.

In a recent conversation with Drug Topics on Over the Counter, Mark Garofoli discusses why men avoid seeking medical help for pain, as well as potential solutions.

The investigational oral, selective NaV1.8 pain signal inhibitor from Vertex Pharmaceuticals demonstrated a favorable benefit/risk profile in 3 phase 3 trials.